NGL Fine-ChemNSE:NGLFINE -2.72%78 ROE % is 16.38% as of Mar. 2026, which is 10% below its 10-year median of 18.10. GuruFocus rates NSE:NGLFINE with a GF Score™ of 78/100 and a GF Value™ of ₹2,836.47 (Fairly Valued). The stock has 8 warning signs investors should review. Among 936 Drug Manufacturers companies, NGL Fine-Chem ranks better than 79.91% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. NGL Fine-Chem's annualized net income for the quarter that ended in Mar. 2026 was ₹539 Mil. NGL Fine-Chem's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was ₹3,292 Mil. Therefore, NGL Fine-Chem's annualized ROE % for the quarter that ended in Mar. 2026 was 16.38%.
The historical rank and industry rank for NGL Fine-Chem's ROE % or its related term are showing as below:
NSE:NGLFINE'
s ROE % Range Over the Past 10 Years
Min: 7.75 Med: 18.1 Max: 44.76
Current: 15.81
During the past 13 years, NGL Fine-Chem's highest ROE % was 44.76%. The lowest was 7.75%. And the median was 18.10%.
NSE:NGLFINE's ROE % is ranked better than 79.91% of 936
companies
in the Drug Manufacturers industry
Industry Median: 5.865
vs NSE:NGLFINE: 15.81
NGL Fine-Chem (NSE:NGLFINE) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
NGL Fine-Chem ROE % Related Terms
NGL Fine-Chem ROE % Historical Data
* Premium members only.
The historical data trend for NGL Fine-Chem's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, NGL Fine-Chem's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NGL Fine-Chem ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, NGL Fine-Chem's ROE % distribution charts can be found below:
* The bar in red indicates where NGL Fine-Chem's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
NGL Fine-Chem (NSE:NGLFINE) has a ROE % of 16.38% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on NGL Fine-Chem and its competitors. This is 10% below median its historical median of 18.10. Over the past decade, NGL Fine-Chem's ROE % has ranged from 7.75 to 44.76. According to the industry distribution chart, NGL Fine-Chem ranks #188 out of 936 companies in the Drug Manufacturers industry, placing it in the top 20.1%.
Is NGL Fine-Chem's ROE % too high?
NGL Fine-Chem's current ROE % of 16.38% is 10% below median its 10-year median of 18.10. Over the past 10 years, this metric has ranged from a low of 7.75 to a high of 44.76. The Drug Manufacturers industry median ROE % is 5.87. NGL Fine-Chem's value of 16.38% is 179.3% above this industry median. Based on the distribution chart, NGL Fine-Chem ranks #188 out of 936 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, NGL Fine-Chem has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does NGL Fine-Chem's ROE % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, NGL Fine-Chem ranks #188 out of 936 companies for ROE %. This places NGL Fine-Chem in the top 20% of its industry — outperforming the majority of peers. The industry median ROE % is 5.87. NGL Fine-Chem's value of 16.38% is 179.3% above this benchmark. Historically, NGL Fine-Chem's own ROE % has ranged from 7.75 to 44.76 over the past decade. While the company's 10-year median is 18.10 vs. the industry median of 5.87, NGL Fine-Chem has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 5.87, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NGL Fine-Chem's current ROE % of 16.38% is 179.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on NGL Fine-Chem and its competitors. For the Drug Manufacturers industry, the median ROE % is 5.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NGL Fine-Chem's current ROE % is 16.38%, which is 10% below median its own 10-year median of 18.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NGL Fine-Chem stock overvalued right now?
Based on GuruFocus' analysis, NGL Fine-Chem (NSE:NGLFINE) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,836.47, compared to a current price of ₹2,989.90 — trading 5.4% above its estimated fair value. The current ROE % is 16.38%, which is 10% below median its 10-year median of 18.10 and 179.3% above the Drug Manufacturers industry median of 5.87. NGL Fine-Chem's overall GF Score™ is 78/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For NGL Fine-Chem (NSE:NGLFINE), the current ROE % is 16.38% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NGL Fine-Chem (NSE:NGLFINE) Overvalued in 2026?
Based on GuruFocus' analysis, NGL Fine-Chem stock appears to be overvalued.
The current stock price of ₹2,989.90 is trading 5.4% above its estimated GF Value™ of ₹2,836.47.
GuruFocus considers NGL Fine-Chem to be Fairly Valued.
Key valuation signals for NSE:NGLFINE:
ROE %: 16.38% (10% below median its 10-year median of 18.10)
GF Value™: ₹2,836.47 vs. price of ₹2,989.90 (5.4% above fair value)
Industry Position: 179.3% above the Drug Manufacturers median (#188 of 936)
No single metric tells the full story. See the NSE:NGLFINE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NGL Fine-Chem Ltd is an Indian company engaged in the pharmaceutical business. It is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health, catering to various companies to custom-manufacture pharmaceuticals. The company's product portfolio comprises animal health APIs such as homidium chloride, nitroxynil, clorsulon, decoquinate, fenbendazole, etc.; human health APIs such as nitazoxanide and atovaquone; drug intermediates and specialty chemicals; and finished dosage forms such as diminazene aceturate granules and homidium chloride tablets. Geographically, the group generates maximum revenue from the Asia-Pacific region, and the rest from India, Europe, the USA, and the rest of the world.
78GF Score
Get the complete analysis for NSE:NGLFINE
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NGLFINE has been successfully added to your 
